Abstract: Communication systems and methods are disclosed that utilize Probability Amplitude Shaping (PAS) and Trellis Coded Modulation (TCM) to transmit short block-length messages. While capacity-approaching codes, such as Low Density Parity Check (LDPC) codes, Turbo codes, and Polar codes, can achieve data rates approaching the Shannon limit at large block-lengths, the performance of these codes can deteriorate dramatically at short block-lengths. Communication systems configured in accordance with various embodiments of the invention can utilize classical codes to encode short block-length messages to achieve communication rates exceeding Polyanskiy's Random Coding Union bound. In several embodiments, message bits are transmitted using a TCM system in which message bits that have been previously encoded by an error detection code are encoded using a convolutional code (CC). In a number of embodiments, the error detection code and the CC are obtained via a joint optimization with respect to a Frame Error Rate bound.

Abstract: The invention relates to the field of biomedicine, in particular to a T cell co-expressing CXCR2 and a Synthetic T-Cell Receptor and Antigen Receptor (STAR) against GPC3, and uses thereof.

Abstract: Compounds and methods for treating insulin resistance, obesity, Type 2 diabetes, Nonalcoholic fatty liver disease (NAFLD), and peroxisome proliferator-activated receptor gamma (PPARy) serine 273 phosphorylation in subjects in need of such therapy.

Abstract: A modified immune effector cell may be one in which the functions of a T cell antigen receptor (TCR) and major histocompatibility complexes (MHCI, MHCII) in the modified immune effector cell are inhibited in a T cell. Such a modified immune effector cell may include a chimeric antigen receptor (CAR) targeting GD2. Such a modified immune effector cell may knock out TCR and HLA-A genes expressed by the cell while recognizing surface antigens of tumor cells, so that multiple effects of improving the anti-tumor effect of CAR-T cells, prolonging the survival time of the cells, and reducing the immune rejection response caused by allogeneic cell therapy may be reduced.

Abstract: Described are a system, method, and computer program product for state compression in stateful machine learning models. The method includes receiving a transaction authorization request for a transaction and loading at least one encoded state of a recurrent neural network (RNN) model from a memory. The method further includes decoding the at least one encoded state by passing each encoded state through a decoder network to provide at least one decoded state. The method further includes generating at least one updated state and an output for the transaction by inputting at least a portion of the transaction authorization request and the at least one decoded state into the RNN model. The method further includes encoding the at least one updated state by passing each updated state through an encoder network to provide at least one encoded updated state, and storing the at least one encoded updated state in the memory.

Abstract: The present invention relates to the technical field of functional materials, and in particular to an amorphous metal oxide hollow multi-shell material and a preparation method therefor and an application thereof. The method includes the following steps: 1) performing a heating reaction on a carbon source aqueous solution, filtering, washing, and drying to obtain a carbon sphere template; 2) dispersing the carbon sphere template obtained in step 1) in a first metal salt solution, heating, adsorbing, and drying to obtain a first solid precursor; 3) dispersing the solid precursor obtained in step 2) in a second metal salt solution again, adsorbing, and drying to obtain a second solid precursor; and 4) calcinating the second solid precursor obtained in step 3) to obtain the amorphous metal oxide hollow multi-shell material.

Abstract: Methods and apparatuses are provided for performing sequence to sequence (Seq2Seq) speech recognition training performed by at least one processor. The method includes acquiring a training set comprising a plurality of pairs of input data and target data corresponding to the input data, encoding the input data into a sequence of hidden states, performing a connectionist temporal classification (CTC) model training based on the sequence of hidden states, performing an attention model training based on the sequence of hidden states, and decoding the sequence of hidden states to generate target labels by independently performing the CTC model training and the attention model training.

Abstract: Detecting fine-grained similarity in image includes determining a core area of a search image by generating an image salient map from a plurality of layers of the search image and determining a connected area based on the image salient map. Feature descriptors are generated from the core area of the search image. A plurality of capsule vectors are generated from different ones of a plurality of keypoints of the feature descriptors. Capsule vectors of the search image are compared with capsule vectors of each image of the dataset to generate a top-K matrix. Similarity scores for the top-K matrix are calculated. One or more image of the dataset having fine-grained similarity with the search image are selected based a bundled similarity score for each image of the dataset. The bundled similarity score is a summation of the similarity scores of the image.

Abstract: The present disclosure provides use of Clostridium ghonii combined with a tumor angiogenesis inhibitor in preparing a pharmaceutical product for treating a tumor. The present disclosure further provides a drug for treating a tumor, where the drug includes active ingredients of Clostridium ghonii and a tumor angiogenesis inhibitor.

Abstract: Various embodiments of the teachings herein include a method for deploying power quality monitoring (PQM) devices. The method may include: determining a maximum number of PQM devices and historical power data of candidate deployment points, wherein the number of the candidate deployment points is greater than the maximum number of the PQM devices; clustering the historical power data of the candidate deployment points, wherein a target number of categories is determined on the basis of a silhouette coefficient of each candidate number of categories and the maximum number of the PQM devices; and determining PQM device deployment points based on the center of each category in the target number of categories.

Abstract: The present application discloses a recombinant Newcastle disease virus genome, a recombinant Newcastle disease virus rNDV-VEGF-Trap containing the genome and a preparation method therefor, a DNA molecule encoding the recombinant Newcastle disease virus genome, and a use of the genome and the recombinant Newcastle disease virus in the preparation of a drug for treating cancer. The recombinant Newcastle disease virus provided by the present application relates to inserting a coding gene of VEGF-Trap into the genome of the recombinant Newcastle disease virus, such that the recombinant Newcastle disease virus obtained therefrom is replicated with a strong replication capability, thereby killing host cancer cells; moreover, the recombinant Newcastle disease virus has reliable safety for non-cancer cells, and shows improved anti-tumor effect and oncolytic efficiency.

Abstract: The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also relates to a preparation method for the solid and the pharmaceutical composition thereof, and an application thereof in the treatment of mental diseases. According to the present disclosure, the lurasidone solid prepared has controllable particle size and has Dv5O particle size of 6 ?m to 110 ?m. The good particle size stability can also he maintained in the pharmaceutical composition. The lurasidone suspension preparation obtained by the method is fast-acting, has a long sustained release period, and can effectively reduce the risk caused by poor patient compliance.

Abstract: An application of a hydrogel in the preparation of products for the treatment of bacterial infection is disclosed. Ferrous ion was used in the antibacterial activity test of Staphylococcus aureus and showed a strong bactericidal effect, which the survival rate of Staphylococcus aureus is less than 0.001%, as well as the survival rate of methicillin-resistant Staphylococcus aureus (MRSA) was less than 0.01%. Ferrous ion hydrogel was used for the treatment of keratitis and skin wound infection. Ferrous ion hydrogel for the treatment of keratitis and skin wound infection, which can significantly reduce the risk of pulmonary MRSA infection, prevented the dissimilation of MRSA to the lung, and alleviated systemic inflammation in the body in a timely and effective manner, revealing the therapeutic potential of ferrous compounds for treatment of Staphylococcus aureus infections, including MRSA.

Abstract: The present disclosure relates to use of a Clostridium ghonii spore combined with pembrolizumab in cancer treatment. It is found for the first time that the Clostridium ghonii spore combined with pembrolizumab can significantly improve a curative effect of colon cancer and reduce a dose of the pembrolizumab, and thus is efficient and low-toxic. Oncolysis by Clostridium ghonii can affect immunogenicity of a tumor microenvironment (TME) by various ways, converts an immunosuppressive state of the TME into an immune-activated state, adjusts the immunosuppressive TME, and breaks an immune tolerance. An optimal combination of the Clostridium ghonii spore and the pembrolizumab thoroughly removes about 20% of mouse tumor tissues. A benefit range of patients with tumors treated by a PD-1 antibody is expanded. The combination even has an obvious curative effect on patients failed the treatment by the PD-1 antibody.

Abstract: One or more systems, devices, computer program products and/or computer-implemented methods of use provided herein relate to detecting a closed ring in a three-dimensional (3D) point cloud via cycle basis. A system can comprise a memory configured to store computer executable components; and a processor configured to execute the computer executable components stored in the memory, wherein the computer executable components can comprise a filtering component that can filter a first undirected graph of a three-dimensional (3D) point cloud, by eliminating one or more edges of the first undirected graph that are longer than an adaptive threshold, wherein filtering the first undirected graph can produce a second undirected graph; and a detection component that can detect a minimum cycle basis of the second undirected graph to determine a cycle path that can traverse an irregular annular shape that is represented by the 3D point cloud.

Abstract: This invention relates to the fields of mRNA vaccines, mRNA therapy, and gene therapy and specifically to the use of gene expression vectors or PCR amplicons containing various 5?UTR sequences followed by coding sequences for in vitro and in vivo production of mRNA or proteins of interest.